Article

Escitalopram in the treatment of social anxiety disorder - Randomised, placebo-controlled, flexible-dosage study

Stellenbosch University, Johannesburg, Gauteng, South Africa
The British Journal of Psychiatry (Impact Factor: 7.34). 04/2005; 186:222-6. DOI: 10.1192/bjp.186.3.222
Source: PubMed

ABSTRACT Selective serotonin reuptake inhibitors are effective in the treatment of social anxiety disorder and are currently regarded as the pharmacotherapy of choice.
To investigate the efficacy and tolerability of escitalopram in the treatment of generalised social anxiety disorder.
Patients with generalised social anxiety disorder were randomised to receive placebo (n=177) or 10-20 mg escitalopram (n=181) in a 12-week, double-blind trial. The primary outcome measure was the mean change from baseline to last assessment in the Liebowitz Social Anxiety Scale (LSAS) total score.
The study showed a statistically superior therapeutic effect for escitalopram compared with placebo on the LSAS total score (P=0.005). There were significantly more responders to treatment for escitalopram than for placebo (54% v. 39%; P<0.01). The clinical relevance of these findings was supported by significant reduction in the work and social components of the Sheehan Disability Scale and by the good tolerability of escitalopram treatment.
Escitalopram was efficacious and well tolerated in the treatment of generalised social anxiety disorder.

1 Follower
 · 
97 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Social anxiety disorder (SAD) is a common mental health problem that tends to be chronic in nature; fortunately, effective pharmacotherapy options exist. The current study provides an updated meta-analytic review of their efficacy and potential guidelines for their application in SAD. Methods: A comprehensive search of the current literature yielded 39 randomized, pill placebo-controlled trials of pharmacotherapy for adults diagnosed with SAD. Data on potential moderators of treatment outcome were collected, as well as data necessary to calculate effect sizes using Hedges's g. Results: The overall effect size of pharmacotherapy for SAD is small to medium (Hedges's g = 0.39). The most effective pharmacotherapy type was phenelzine (Hedges's g = 1.14), followed by paroxetine (Hedges's g = 0.49), venlafaxine ER (Hedges's g = 0.45) and moclobemide (Hedges's g = 0.23). Conclusion: Effect sizes were not moderated by age, sex, length of treatment, diagnostic subtype initial severity, maximum potential dose, or publication year. It is concluded that pharmacotherapy is effective for treating SAD, but there is considerable variation and room for further improvement. Future directions may include pharmacological enhancement of psychological processes, such as d-cycloserine augmentation of exposure procedures.
    Expert Opinion on Pharmacotherapy 10/2014; 15(16):1-11. DOI:10.1517/14656566.2014.955472 · 3.09 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Accession Number: 79354328; Öyekçin, Demet Güleç 1; Email Address: gulecdemet@yahoo.com Yıldız, Deniz 2; Affiliation: 1: Yrd. Doç. Dr., 18 Mart Üniversitesi, Tıp Fakültesi, Psikiyatri AD, Çanakkale-Türkiye 2: Ar. Gör. Dr., 18 Mart Üniversitesi, Tıp Fakültesi, Psikiyatri AD, Çanakkale-Türkiye; Source Info: Mar2012, Vol. 2 Issue 1, p34; Subject Term: PERSONALITY disorders -- Treatment; Subject Term: PSYCHIATRIC drugs; Subject Term: DRUGS -- Effectiveness; Subject Term: MOOD stabilizers; Subject Term: ANTIDEPRESSANTS; Author-Supplied Keyword: borderline personality disorder; Author-Supplied Keyword: personality disorders; Author-Supplied Keyword: pharmacotherapy; Author-Supplied Keyword: borderline kişilik bozukluğu; Author-Supplied Keyword: farmakoterapi; Author-Supplied Keyword: kişilik bozuklukları; Language of Keywords: English; Language of Keywords: Turkish; NAICS/Industry Codes: 325411 Medicinal and Botanical Manufacturing; NAICS/Industry Codes: 325410 Pharmaceutical and medi
    03/2012; 2(1):34-46.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pharmacotherapy of Personality Disorders Objective: Prevalence of personality disorders have been reported as 10-13% in general population, 30-50% in psychiatric patients, and 15% in psychiatric outpatients. The most common personality disorders are respectively borderline, antisocial, schizotypal, and avoidant. There has been no specific pharmacological approach for the treatment of personality disorders that have different clinical features with various co-morbid psychiatric disorders. The aim of this report is to review the efficacy of psychotropic medications used for the treatment of personality disorders. Methods: By using "borderline, antisocial, schizotypal, narcissistic, obsessive compulsive, avoidant personality, and pharmacotherapy" as keywords at the Pubmed database we primarily searched for the double blind, placebo controlled, randomized trials and also included some of the open label trials. Results: Most of the research on this topic was on pharmacotherapy of borderline personality disorder. Polypharmacy, that has been used widely in treatment of these cases, has been reported ineffective in most of the patients. The antidepressants have been replaced by mood stabilizers. The antidepressants and mood stabilizers have been reported to decrease mood symptoms like anger, depression, dysphoria, and to enhance adherence to psychotherapy. The most effective mood stabilizer was divalproex. The antipsychotics have been recommended to be used at psychotic and behavioral symptomatology. At the treatment of antisocial personality disorder CBT is recommended and there was no evidence based pharmacotherapy. In the treatment of schizotypal personality disorder, the antipsychotics have been reported effective. Pergolide and guanfacine have been reported to be useful in the treatment of cognitive disorders. The first line treatment options of avoidant personality disorder are venlafaxine and SSRIs. Conclusions: Most of the studies in literature have been focused at borderline personality disorder that has been difficult to treat. According to the guidelines, psychotherapy is the first line treatment for personality disorders. Pharmacotherapy has been reported to increase the efficiency of psychotherapy in BPD which presents with various symptoms of mood, cognition, and behavior. The studies in the literature report that Polypharmacy is not useful for these patients contrary to the popular belief. The research about other personality disorders is limited. More clear understanding of etiopathogenesis of personality disorders; would be helpful in development of more effective pharmacological agents in their treatment.
    03/2012; 2(1):31-46. DOI:10.5455/jmood.20120328094704

Full-text

Download
20 Downloads
Available from
Jun 23, 2014